1. Search Result
Search Result
Results for "

immunological synapse

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

4

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991155

    JNJ-79635322; JNJ-5322

    CD3 TNF Receptor Cancer
    Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
    Ramantamig
  • HY-P990925

    BLYG8824A; RG6286

    CD3 Inflammation/Immunology
    Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .
    Linclatamig
  • HY-P991490

    CD38 CD3 TNF Receptor Cancer
    ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .
    ISB2001
  • HY-185659

    CD22 Apoptosis Akt ERK Inflammation/Immunology
    6'-BPANeuGc is a CD22-targeting ligand. 6'-BPANeuGc suppresses BCR activation, recruits CD22 to B cell immunological synapses, initiates inhibitory signals, induces B cell apoptosis. 6'-BPANeuGc inhibits calcium flux, and inhibits Akt and Erk activation. 6'-BPANeuGc can be used for research on immune system diseases .
    6'-BPANeuGc
  • HY-P992457

    Glycoprotein VI Interleukin Related Cancer
    SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3 + solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma .
    SAR444200

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: